Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 12:50 pm PT. CEO Gerrit Klaerner will discuss the company's initiatives and recent developments.

A live webcast of the event will be available on the Tricida website, with an archive accessible post-event. The company is focused on developing veverimer, a novel treatment for metabolic acidosis linked to chronic kidney disease. This condition affects around three million CKD patients in the U.S., with no existing FDA-approved therapies.

SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42^nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow chronic kidney disease (CKD) progression in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. There are no FDA-approved treatments for chronic metabolic acidosis. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

When will Tricida present at the Goldman Sachs Healthcare Conference?

Tricida will present on June 9, 2021, at 12:50 pm PT.

Who will represent Tricida at the conference?

Gerrit Klaerner, the CEO, will represent Tricida.

What will Tricida discuss during the conference?

Tricida will provide an overview of the company, business updates, and progress on key initiatives.

How can I watch Tricida's presentation?

The presentation will be live-streamed on Tricida's website, with an archive available after.

What is veverimer and its significance?

Veverimer is a drug candidate designed to treat metabolic acidosis and slow chronic kidney disease progression.